Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association discusses pharmacists’ role in diabetes and CKD care from ASN Kidney Week 2026
|Videos|September 2, 2015
Pharmacists and Future HRSA Policy Updates
Chris Hatwig, MS, FASHP of Apexus discusses what HRSA policy updates, including 340B "mega guidance," are poised to affect health-system pharmacists.
Advertisement
Chris Hatwig, MS, FASHP of Apexus discusses what HRSA policy updates, including 340B "mega guidance," are poised to affect health-system pharmacists.
This video was shot at ASHP's Summer Meetings and Exposition in Denver in June 2015.
Advertisement
Related to this article
Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
Young adults who vaped daily but never smoked had lower flow-mediated dilation and peak oxygen uptake than peers who used neither product.
Pharmacists can reduce COVID-19 vaccine hesitancy through honest, nonjudgmental communication and by using every patient touchpoint as an opportunity to offer vaccination.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Happens Before the First Dose? 5 Steps That Shape Lung Cancer Treatment
2
Diabetes Awareness Month Opens Amid New T1D, T2D Approvals
3
October 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
4
Full IDWeek Data Highlights 31-Valent Pneumococcal Conjugate Vaccine Candidate in Adults
5